{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T10:56:28Z","timestamp":1773744988198,"version":"3.50.1"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-024-10461-3","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T19:08:40Z","timestamp":1732734520000},"page":"271-286","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Hyperkalemia management: a multidisciplinary expert panel\u2019s perspective on the role of new potassium binders"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3019-5956","authenticated-orcid":false,"given":"C\u00e2ndida","family":"Fonseca","sequence":"first","affiliation":[]},{"given":"Cristina","family":"Garagarza","sequence":"additional","affiliation":[]},{"given":"Gil","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Gra\u00e7a","family":"Caires","sequence":"additional","affiliation":[]},{"given":"Irene","family":"Marques","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 Ant\u00f3nio","family":"Lopes","sequence":"additional","affiliation":[]},{"given":"Patr\u00edcia","family":"Branco","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Alves","sequence":"additional","affiliation":[]},{"given":"An\u00edbal","family":"Ferreira","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"key":"10461_CR1","doi-asserted-by":"crossref","unstructured":"Hunter, R.W. and M.A. Bailey, Hyperkalemia: pathophysiology, risk factors and consequences. Nephrol Dial Transplant, 2019. 34(Suppl 3): p. iii2-iii11.","DOI":"10.1093\/ndt\/gfz206"},{"issue":"36","key":"10461_CR2","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599\u20133726","journal-title":"Eur Heart J"},{"issue":"5","key":"10461_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/emp2.12572","volume":"2","author":"Z Rafique","year":"2021","unstructured":"Rafique Z et al (2021) Hyperkalemia management in the emergency department: an expert panel consensus. J Am Coll Emerg Physicians Open 2(5):e12572","journal-title":"J Am Coll Emerg Physicians Open"},{"issue":"4s","key":"10461_CR4","first-page":"S117","volume":"105","author":"KDIGO","year":"2024","unstructured":"KDIGO (2024) clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105(4s):S117-s314","journal-title":"Kidney Int"},{"issue":"1","key":"10461_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40119-022-00289-z","volume":"12","author":"NL Lariv\u00e9e","year":"2023","unstructured":"Lariv\u00e9e NL et al (2023) Hyperkalemia: prevalence, predictors and emerging treatments. Cardiol Ther 12(1):35\u201363","journal-title":"Cardiol Ther"},{"issue":"5","key":"10461_CR6","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.ekir.2021.02.038","volume":"6","author":"I Hougen","year":"2021","unstructured":"Hougen I et al (2021) Hyperkalemia and its association with mortality, cardiovascular events, hospitalizations, and intensive care unit admissions in a population-based retrospective cohort. Kidney Int Rep 6(5):1309\u20131316","journal-title":"Kidney Int Rep"},{"issue":"14","key":"10461_CR7","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.3390\/jcm11143970","volume":"11","author":"G Romero-Gonz\u00e1lez","year":"2022","unstructured":"Romero-Gonz\u00e1lez G et al (2022) The \u201cFIFTY SHADOWS\u201d of the RALES trial: lessons about the potential risk of dietary potassium supplementation in patients with chronic kidney disease. J Clin Med 11(14):3970","journal-title":"J Clin Med"},{"issue":"7","key":"10461_CR8","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41581-024-00820-6","volume":"20","author":"A Francis","year":"2024","unstructured":"Francis A et al (2024) Chronic kidney disease and the global public health agenda: an international consensus. Nature Reviews Nephrology 20(7):473\u2013485","journal-title":"Nature Reviews Nephrology"},{"issue":"17","key":"10461_CR9","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","volume":"118","author":"G Savarese","year":"2023","unstructured":"Savarese G et al (2023) Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res 118(17):3272\u20133287","journal-title":"Cardiovasc Res"},{"issue":"6","key":"10461_CR10","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1038\/s41440-024-01665-z","volume":"47","author":"EJ Johns","year":"2024","unstructured":"Johns EJ (2024) Functional insights into the cardiorenal syndrome. Hypertens Res 47(6):1747\u20131749","journal-title":"Hypertens Res"},{"issue":"4","key":"10461_CR11","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s10741-020-10069-3","volume":"26","author":"J Silva-Cardoso","year":"2021","unstructured":"Silva-Cardoso J et al (2021) Management of RAASi-associated hyperkalemia in patients with cardiovascular disease. Heart Fail Rev 26(4):891\u2013896","journal-title":"Heart Fail Rev"},{"issue":"2","key":"10461_CR12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s11739-023-03427-0","volume":"19","author":"L De Nicola","year":"2024","unstructured":"De Nicola L et al (2024) Recommendations for the management of hyperkalemia in patients receiving renin\u2013angiotensin\u2013aldosterone system inhibitors. Intern Emerg Med 19(2):295\u2013306","journal-title":"Intern Emerg Med"},{"issue":"3","key":"10461_CR13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1159\/000479802","volume":"46","author":"AJ Collins","year":"2017","unstructured":"Collins AJ et al (2017) Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and\/or diabetes. Am J Nephrol 46(3):213\u2013221","journal-title":"Am J Nephrol"},{"issue":"1","key":"10461_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/jphsr\/rmaa004","volume":"12","author":"A Sharma","year":"2021","unstructured":"Sharma A et al (2021) Healthcare resource utilization and costs associated with hyperkalemia in a large managed care population. J Pharm Health Serv Res 12(1):35\u201341","journal-title":"J Pharm Health Serv Res"},{"issue":"37","key":"10461_CR15","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA et al (2023) 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 44(37):3627\u20133639","journal-title":"Eur Heart J"},{"issue":"3","key":"10461_CR16","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.mayocp.2020.06.014","volume":"96","author":"BF Palmer","year":"2021","unstructured":"Palmer BF et al (2021) Clinical management of hyperkalemia. Mayo Clin Proc 96(3):744\u2013762","journal-title":"Mayo Clin Proc"},{"issue":"7\u20138","key":"10461_CR17","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1159\/000531102","volume":"54","author":"J An","year":"2023","unstructured":"An J et al (2023) Discontinuation of renin-angiotensin-aldosterone system inhibitors secondary to hyperkalemia translates into higher cardiorenal outcomes. Am J Nephrol 54(7\u20138):258\u2013267","journal-title":"Am J Nephrol"},{"issue":"8","key":"10461_CR18","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1093\/ndt\/gfae016","volume":"39","author":"MK Svensson","year":"2024","unstructured":"Svensson MK et al (2024) Hyperkalaemia-related reduction of RAASi treatment associates with more subsequent inpatient care. Nephrology Dialysis Transplantation 39(8):1258","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"8","key":"10461_CR19","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1001\/jamainternmed.2019.0631","volume":"179","author":"JA Noel","year":"2019","unstructured":"Noel JA et al (2019) Risk of Hospitalization for serious adverse gastrointestinal events associated with sodium polystyrene sulfonate use in patients of advanced age. JAMA Intern Med 179(8):1025\u20131033","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10461_CR20","volume":"16","author":"ES Sinnathamby","year":"2024","unstructured":"Sinnathamby ES et al (2024) Hyperkalemia: pharmacotherapies and clinical considerations. Cureus 16(1):e52994","journal-title":"Cureus"},{"key":"10461_CR21","doi-asserted-by":"publisher","unstructured":"Vidal H, et al (2024) Calcium polystyrene sulfonate induced colitis: advanced characterization of crystal nature with infrared spectroscopy. Clinical Kidney Journal 17(8): https:\/\/doi.org\/10.1093\/ckj\/sfae210","DOI":"10.1093\/ckj\/sfae210"},{"key":"10461_CR22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ejim.2023.08.022","volume":"119","author":"S Paolillo","year":"2024","unstructured":"Paolillo S et al (2024) Novel potassium binders to optimize RAASi therapy in heart failure: a systematic review and meta-analysis. Eur J Intern Med 119:109\u2013117","journal-title":"Eur J Intern Med"},{"issue":"1","key":"10461_CR23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/ehf2.14588","volume":"11","author":"M Abuelazm","year":"2024","unstructured":"Abuelazm M et al (2024) The efficacy and safety of new potassium binders on renin-angiotensin-aldosterone system inhibitor optimization in heart failure patients: a systematic review and meta-analysis. ESC Heart Fail 11(1):28\u201343","journal-title":"ESC Heart Fail"},{"issue":"1","key":"10461_CR24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.kint.2019.09.018","volume":"97","author":"CM Clase","year":"2020","unstructured":"Clase CM et al (2020) Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 97(1):42\u201361","journal-title":"Kidney Int"},{"issue":"1","key":"10461_CR25","first-page":"59","volume":"107","author":"MJ Kim","year":"2023","unstructured":"Kim MJ, Valerio C, Knobloch GK (2023) Potassium disorders: hypokalemia and hyperkalemia. Am Fam Physician 107(1):59\u201370","journal-title":"Am Fam Physician"},{"issue":"9","key":"10461_CR26","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s40264-014-0196-1","volume":"37","author":"C Ben Salem","year":"2014","unstructured":"Ben Salem C et al (2014) Drug-INDUCED HYPERKALEmia. Drug Saf 37(9):677\u2013692","journal-title":"Drug Saf"},{"issue":"7","key":"10461_CR27","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.ekir.2023.04.016","volume":"8","author":"D Massicotte-Azarniouch","year":"2023","unstructured":"Massicotte-Azarniouch D et al (2023) Managing hyperkalemia in the modern era: a case-based approach. Kidney Int Rep 8(7):1290\u20131300","journal-title":"Kidney Int Rep"},{"issue":"22","key":"10461_CR28","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1016\/j.jacc.2020.04.021","volume":"75","author":"JP Ferreira","year":"2020","unstructured":"Ferreira JP et al (2020) Abnormalities of potassium in heart failure: JACC State-of-the-Art Review. J Am Coll Cardiol 75(22):2836\u20132850","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10461_CR29","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/0092-8674(90)90186-I","volume":"61","author":"ER Fearon","year":"1990","unstructured":"Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61(5):759\u2013767","journal-title":"Cell"},{"issue":"4","key":"10461_CR30","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/ckj\/sfab243","volume":"15","author":"T Humphrey","year":"2022","unstructured":"Humphrey T et al (2022) How common is hyperkalaemia? A systematic review and meta-analysis of the prevalence and incidence of hyperkalaemia reported in observational studies. Clin Kidney J 15(4):727\u2013737","journal-title":"Clin Kidney J"},{"issue":"17","key":"10461_CR31","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1093\/eurheartj\/ehy100","volume":"39","author":"CP Kovesdy","year":"2018","unstructured":"Kovesdy CP et al (2018) Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis. Eur Heart J 39(17):1535\u20131542","journal-title":"Eur Heart J"},{"issue":"3","key":"10461_CR32","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/ehjcvp\/pvy015","volume":"4","author":"GMC Rosano","year":"2018","unstructured":"Rosano GMC et al (2018) Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. European Heart Journal - Cardiovascular Pharmacotherapy 4(3):180\u2013188","journal-title":"European Heart Journal - Cardiovascular Pharmacotherapy"},{"key":"10461_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n189","volume":"372","author":"A Albasri","year":"2021","unstructured":"Albasri A et al (2021) Association between antihypertensive treatment and adverse events: systematic review and meta-analysis. BMJ 372:n189","journal-title":"BMJ"},{"issue":"1","key":"10461_CR34","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12882-022-03054-5","volume":"24","author":"E Kanda","year":"2023","unstructured":"Kanda E et al (2023) Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia. BMC Nephrol 24(1):18","journal-title":"BMC Nephrol"},{"issue":"8","key":"10461_CR35","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/ejhf.1199","volume":"20","author":"M Trevisan","year":"2018","unstructured":"Trevisan M et al (2018) Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. Eur J Heart Fail 20(8):1217\u20131226","journal-title":"Eur J Heart Fail"},{"issue":"22","key":"10461_CR36","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012655","volume":"8","author":"C Linde","year":"2019","unstructured":"Linde C et al (2019) Real-world associations of renin-angiotensin-aldosterone system inhibitor dose, hyperkalemia, and adverse clinical outcomes in a cohort of patients with new-onset chronic kidney disease or heart failure in the United Kingdom. J Am Heart Assoc 8(22):e012655","journal-title":"J Am Heart Assoc"},{"key":"10461_CR37","doi-asserted-by":"crossref","unstructured":"Polson M, et al (2017) Clinical and economic impact of hyperkalemia in patients with chronic kidney disease and heart failure. J Manag Care Spec Pharm 23(4-a Suppl): p. S2-s9.","DOI":"10.18553\/jmcp.2017.23.4-a.s2a"},{"issue":"5","key":"10461_CR38","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/ejhf.1175","volume":"20","author":"LH Lund","year":"2018","unstructured":"Lund LH, Pitt B (2018) Is hyperkalaemia in heart failure a risk factor or a risk marker? Implications for renin-angiotensin-aldosterone system inhibitor use. Eur J Heart Fail 20(5):931\u2013932","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10461_CR39","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12245-022-00422-8","volume":"15","author":"LA Raffee","year":"2022","unstructured":"Raffee LA et al (2022) Clinical and electrocardiogram presentations of patients with high serum potassium concentrations within emergency settings: a prospective study. Int J Emerg Med 15(1):23","journal-title":"Int J Emerg Med"},{"key":"10461_CR40","volume-title":"Hyperkalemia, in StatPearls","author":"LV Simon","year":"2024","unstructured":"Simon LV, Hashmi MF, Farrell MW (2024) Hyperkalemia, in StatPearls. StatPearls Publishing LLC"},{"issue":"6","key":"10461_CR41","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/nep.14281","volume":"29","author":"DYH Yap","year":"2024","unstructured":"Yap DYH et al (2024) Consensus statement on the management of hyperkalaemia-An Asia-Pacific perspective. Nephrology (Carlton) 29(6):311\u2013324","journal-title":"Nephrology (Carlton)"},{"issue":"6","key":"10461_CR42","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.nefro.2023.05.004","volume":"43","author":"A Ortiz","year":"2023","unstructured":"Ortiz A et al (2023) Documento de consenso sobre el abordaje de la hiperpotasemia. Nefrologia 43(6):765\u2013782","journal-title":"Nefrologia"},{"key":"10461_CR43","unstructured":"Alfonzo A, et al (2023) Treatment of acute hyperkalaemia in adults, in Clinical Practice Guidelines."},{"issue":"17","key":"10461_CR44","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA et al (2022) 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 79(17):e263\u2013e421","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10461_CR45","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1177\/10600280231209968","volume":"58","author":"A Rydell","year":"2023","unstructured":"Rydell A et al (2023) Effectiveness of patiromer versus sodium zirconium cyclosilicate for the management of acute hyperkalemia. Ann Pharmacother 58(8):790\u2013795","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10461_CR46","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12882-023-03145-x","volume":"24","author":"AE Ca\u00f1as","year":"2023","unstructured":"Ca\u00f1as AE et al (2023) A randomized study to compare oral potassium binders in the treatment of acute hyperkalemia. BMC Nephrol 24(1):89","journal-title":"BMC Nephrol"},{"issue":"3","key":"10461_CR47","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.xkme.2021.01.005","volume":"3","author":"GL Bakris","year":"2021","unstructured":"Bakris GL et al (2021) Hyperkalemia management in older adults with diabetic kidney disease receiving renin-angiotensin-aldosterone system inhibitors: a post hoc analysis of the AMETHYST-DN clinical trial. Kidney Med 3(3):360-367.e1","journal-title":"Kidney Med"},{"issue":"10","key":"10461_CR48","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.3390\/nu14102071","volume":"14","author":"C Garagarza","year":"2022","unstructured":"Garagarza C et al (2022) Potassium intake-(un)expected non-predictor of higher serum potassium levels in hemodialysis DASH Diet Consumers. Nutrients 14(10):2071","journal-title":"Nutrients"},{"key":"10461_CR49","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/CE.S129555","volume":"12","author":"MV Beccari","year":"2017","unstructured":"Beccari MV, Meaney CJ (2017) Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review. Core Evid 12:11\u201324","journal-title":"Core Evid"},{"issue":"9","key":"10461_CR50","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000001037","volume":"6","author":"K Schnelle","year":"2020","unstructured":"Schnelle K et al (2020) Largest experience of safety and efficacy of patiromer in solid organ transplant. Transplant Direct 6(9):e595","journal-title":"Transplant Direct"},{"issue":"2","key":"10461_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.trre.2021.100611","volume":"35","author":"B Almalki","year":"2021","unstructured":"Almalki B et al (2021) Management of hyperkalemia: a focus on kidney transplant recipients. Transplant Rev 35(2):100611","journal-title":"Transplant Rev"},{"issue":"4","key":"10461_CR52","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s11154-021-09677-7","volume":"22","author":"JG Rizk","year":"2021","unstructured":"Rizk JG et al (2021) Mechanisms and management of drug-induced hyperkalemia in kidney transplant patients. Rev Endocr Metab Disord 22(4):1157\u20131170","journal-title":"Rev Endocr Metab Disord"},{"key":"10461_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2021.100635","volume":"95","author":"DB Shrestha","year":"2021","unstructured":"Shrestha DB et al (2021) Patiromer and sodium zirconium cyclosilicate in treatment of hyperkalemia: a systematic review and meta-analysis. Curr Ther Res Clin Exp 95:100635","journal-title":"Curr Ther Res Clin Exp"},{"key":"10461_CR54","doi-asserted-by":"crossref","unstructured":"Rosano GMC, Spoletini I, and Agewall S (2019) Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate. European Heart Journal Supplements 21(Supplement_A): A28-A33.","DOI":"10.1093\/eurheartj\/suy035"},{"issue":"4","key":"10461_CR55","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/phar.1906","volume":"37","author":"CJ Meaney","year":"2017","unstructured":"Meaney CJ et al (2017) Systematic review and meta-analysis of patiromer and sodium zirconium cyclosilicate: a new armamentarium for the treatment of hyperkalemia. Pharmacotherapy 37(4):401\u2013411","journal-title":"Pharmacotherapy"},{"issue":"10","key":"10461_CR56","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/ejhf.402","volume":"17","author":"B Pitt","year":"2015","unstructured":"Pitt B et al (2015) Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail 17(10):1057\u20131065","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"10461_CR57","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1093\/ckj\/sfad053","volume":"16","author":"JO Burton","year":"2023","unstructured":"Burton JO et al (2023) Rationale and design of CONTINUITY: a Phase 4 randomized controlled trial of continued post-discharge sodium zirconium cyclosilicate treatment versus standard of care for hyperkalemia in chronic kidney disease. Clin Kidney J 16(7):1160\u20131169","journal-title":"Clin Kidney J"},{"key":"10461_CR58","unstructured":"Veltassa [prescribing information]. 2018: Relypsa Inc."},{"key":"10461_CR59","unstructured":"Veltassa [summary of product characteristics]. 2018: Vifor Fresenius Medical Care Renal Pharma."},{"issue":"6","key":"10461_CR60","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/acem.13954","volume":"27","author":"WF Peacock","year":"2020","unstructured":"Peacock WF et al (2020) Emergency potassium normalization treatment including sodium zirconium cyclosilicate: a phase II, randomized, double-blind, placebo-cONTROLLED STUdy (ENERGIZE). Acad Emerg Med 27(6):475\u2013486","journal-title":"Acad Emerg Med"},{"key":"10461_CR61","unstructured":"Lokelma [prescribing information]. 2018: AstraZeneca Pharmaceuticals."},{"key":"10461_CR62","unstructured":"Lokelma [summary of product characteristics]. 2018: AstraZeneca AB."},{"issue":"7","key":"10461_CR63","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","volume":"32","author":"B Pitt","year":"2011","unstructured":"Pitt B et al (2011) Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 32(7):820\u2013828","journal-title":"Eur Heart J"},{"issue":"2","key":"10461_CR64","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/jama.2015.7446","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL et al (2015) Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA 314(2):151\u2013161","journal-title":"JAMA"},{"key":"10461_CR65","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/DHPS.S338579","volume":"14","author":"G Colbert","year":"2022","unstructured":"Colbert G, Sannapaneni S, Lerma EV (2022) Clinical efficacy, safety, tolerability, and real-world data of patiromer for the treatment of hyperkalemia. Drug Healthc Patient Saf 14:87\u201396","journal-title":"Drug Healthc Patient Saf"},{"issue":"5","key":"10461_CR66","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1177\/1074248416629549","volume":"21","author":"L Li","year":"2016","unstructured":"Li L et al (2016) Mechanism of action and pharmacology of patiromer, a nonabsorbed cross-linked polymer that lowers serum potassium concentration in patients with hyperkalemia. J Cardiovasc Pharmacol Ther 21(5):456\u2013465","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"1","key":"10461_CR67","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2215\/CJN.04500418","volume":"14","author":"DA Bushinsky","year":"2019","unstructured":"Bushinsky DA et al (2019) Effects of the potassium-binding polymer patiromer on markers of mineral metabolism. Clin J Am Soc Nephrol 14(1):103\u2013110","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10461_CR68","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ekir.2018.10.020","volume":"4","author":"CP Kovesdy","year":"2019","unstructured":"Kovesdy CP et al (2019) Real-world evaluation of patiromer for the treatment of hyperkalemia in hemodialysis Patients. Kidney Int Rep 4(2):301\u2013309","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10461_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2023.100757","volume":"6","author":"Y Obi","year":"2024","unstructured":"Obi Y et al (2024) Long-term patiromer use and outcomes among US veterans With hyperkalemia and CKD: a propensity-matched cohort study. Kidney Med 6(1):100757","journal-title":"Kidney Med"},{"issue":"3","key":"10461_CR70","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1410853","volume":"372","author":"MR Weir","year":"2015","unstructured":"Weir MR et al (2015) Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 372(3):211\u2013221","journal-title":"N Engl J Med"},{"issue":"6","key":"10461_CR71","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1177\/1074248418788334","volume":"23","author":"RA Kloner","year":"2018","unstructured":"Kloner RA et al (2018) Effect of patiromer in hyperkalemic patients taking and not taking RAAS inhibitors. J Cardiovasc Pharmacol Ther 23(6):524\u2013531","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"2","key":"10461_CR72","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1080\/00325481.2019.1706920","volume":"132","author":"CP Kovesdy","year":"2020","unstructured":"Kovesdy CP et al (2020) Real-world management of hyperkalemia with patiromer among United States Veterans. Postgrad Med 132(2):176\u2013183","journal-title":"Postgrad Med"},{"issue":"5","key":"10461_CR73","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1159\/000451067","volume":"44","author":"DA Bushinsky","year":"2016","unstructured":"Bushinsky DA et al (2016) Patiromer decreases serum potassium and phosphate levels in patients on hemodialysis. Am J Nephrol 44(5):404\u2013410","journal-title":"Am J Nephrol"},{"issue":"1","key":"10461_CR74","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/acem.13868","volume":"27","author":"Z Rafique","year":"2020","unstructured":"Rafique Z et al (2020) Patiromer for treatment of hyperkalemia in the emergency department: a pilot study. Acad Emerg Med 27(1):54\u201360","journal-title":"Acad Emerg Med"},{"issue":"1","key":"10461_CR75","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.45236","volume":"5","author":"KE Di Palo","year":"2022","unstructured":"Di Palo KE, Sinnett MJ, Goriacko P (2022) Assessment of patiromer monotherapy for hyperkalemia in an acute care setting. JAMA Netw Open 5(1):e2145236","journal-title":"JAMA Netw Open"},{"issue":"10208","key":"10461_CR76","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","volume":"394","author":"R Agarwal","year":"2019","unstructured":"Agarwal R et al (2019) Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 394(10208):1540\u20131550","journal-title":"Lancet"},{"issue":"41","key":"10461_CR77","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1093\/eurheartj\/ehac401","volume":"43","author":"J Butler","year":"2022","unstructured":"Butler J et al (2022) Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. Eur Heart J 43(41):4362\u20134373","journal-title":"Eur Heart J"},{"issue":"2","key":"10461_CR78","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1002\/ehf2.14268","volume":"10","author":"JC Tardif","year":"2023","unstructured":"Tardif JC et al (2023) Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure. ESC Heart Fail 10(2):1066\u20131076","journal-title":"ESC Heart Fail"},{"issue":"3","key":"10461_CR79","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1056\/NEJMoa1411487","volume":"372","author":"DK Packham","year":"2015","unstructured":"Packham DK et al (2015) Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med 372(3):222\u2013231","journal-title":"N Engl J Med"},{"issue":"21","key":"10461_CR80","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1001\/jama.2014.15688","volume":"312","author":"M Kosiborod","year":"2014","unstructured":"Kosiborod M et al (2014) Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA 312(21):2223\u20132233","journal-title":"JAMA"},{"issue":"1","key":"10461_CR81","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/ndt\/gfz285","volume":"36","author":"SD Roger","year":"2021","unstructured":"Roger SD et al (2021) Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild\/moderate versus severe\/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study. Nephrol Dial Transplant 36(1):137\u2013150","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"10461_CR82","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/ejhf.300","volume":"17","author":"SD Anker","year":"2015","unstructured":"Anker SD et al (2015) Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. Eur J Heart Fail 17(10):1050\u20131056","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"10461_CR83","volume":"15","author":"X Qu","year":"2023","unstructured":"Qu X, Hua Y, Khan BA (2023) A real-world experience of hyperkalemia management using sodium zirconium cyclosilicate in chronic hemodialysis: a multicenter clinical audit. Cureus 15(9):e45058","journal-title":"Cureus"},{"issue":"1","key":"10461_CR84","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12882-021-02569-7","volume":"23","author":"S Fishbane","year":"2022","unstructured":"Fishbane S et al (2022) Potassium responses to sodium zirconium cyclosilicate in hyperkalemic hemodialysis patients: post-hoc analysis of DIALIZE. BMC Nephrol 23(1):59","journal-title":"BMC Nephrol"},{"issue":"6","key":"10461_CR85","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1007\/s12325-023-02518-w","volume":"40","author":"A Agiro","year":"2023","unstructured":"Agiro A et al (2023) Real-world modifications of renin-angiotensin-aldosterone system inhibitors in patients with hyperkalemia initiating sodium zirconium cyclosilicate therapy: the OPTIMIZE I study. Adv Ther 40(6):2886\u20132901","journal-title":"Adv Ther"},{"key":"10461_CR86","doi-asserted-by":"crossref","unstructured":"Onogi C, et al (2024) Mortality and hyperkalaemia-associated hospitalisation in patients with chronic kidney disease: comparison of sodium zirconium cyclosilicate and sodium\/calcium polystyrene sulfonate. Clin Kidney J 17(2): sfae021","DOI":"10.1093\/ckj\/sfae021"},{"key":"10461_CR87","doi-asserted-by":"crossref","unstructured":"Rastogi A, et al (2024) Maintained renin\u2013angiotensin\u2013aldosterone system inhibitor therapy with sodium zirconium cyclosilicate following a hyperkalaemia episode: a multicountry cohort study. Clinical Kidney Journal 17(5): sfae083","DOI":"10.1093\/ckj\/sfae083"},{"issue":"9","key":"10461_CR88","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.cardfail.2022.04.003","volume":"28","author":"M Zhuo","year":"2022","unstructured":"Zhuo M et al (2022) Risk of hospitalization for heart failure in patients with hyperkalemia treated with sodium zirconium cyclosilicate versus patiromer. J Card Fail 28(9):1414\u20131423","journal-title":"J Card Fail"},{"issue":"9","key":"10461_CR89","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1681\/ASN.2019050450","volume":"30","author":"S Fishbane","year":"2019","unstructured":"Fishbane S et al (2019) A phase 3b, randomized, double-blind, placebo-controlled study of sodium zirconium cyclosilicate for reducing the incidence of predialysis hyperkalemia. J Am Soc Nephrol 30(9):1723\u20131733","journal-title":"J Am Soc Nephrol"},{"key":"10461_CR90","doi-asserted-by":"crossref","unstructured":"Sumida K, et al (2023) New insights into dietary approaches to potassium management in chronic kidney disease. Journal of Renal Nutrition 33(6 Supplement): S6-S12","DOI":"10.1053\/j.jrn.2022.12.003"},{"key":"10461_CR91","doi-asserted-by":"crossref","unstructured":"Provenzano M, et al (2018) Competing-risk analysis of death and end stage kidney disease by hyperkalaemia status in non-dialysis chronic kidney disease patients receiving stable nephrology care. J Clin Med 7(12)","DOI":"10.3390\/jcm7120499"},{"issue":"7","key":"10461_CR92","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.repc.2021.04.007","volume":"41","author":"H Vasconcelos","year":"2022","unstructured":"Vasconcelos H et al (2022) Hyperkalemia as a limiting factor of neurohormonal blockade\/modulation in everyday clinical practice. Rev Port Cardiol 41(7):521\u2013527","journal-title":"Rev Port Cardiol"},{"issue":"3","key":"10461_CR93","doi-asserted-by":"publisher","first-page":"264.e9","DOI":"10.1016\/j.amjmed.2012.08.016","volume":"126","author":"Z Harel","year":"2013","unstructured":"Harel Z et al (2013) Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am J Med 126(3):264.e9\u201324","journal-title":"Am J Med"},{"issue":"2","key":"10461_CR94","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/ckj\/sfac234","volume":"16","author":"R Agarwal","year":"2023","unstructured":"Agarwal R et al (2023) A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease. Clin Kidney J 16(2):293\u2013302","journal-title":"Clin Kidney J"},{"issue":"3","key":"10461_CR95","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40801-021-00254-7","volume":"8","author":"P Rossignol","year":"2021","unstructured":"Rossignol P et al (2021) Safety and tolerability of the potassium binder patiromer from a global pharmacovigilance database collected over 4 years compared with data from the clinical trial program. Drugs Real World Outcomes 8(3):315\u2013323","journal-title":"Drugs Real World Outcomes"},{"issue":"2","key":"10461_CR96","doi-asserted-by":"publisher","first-page":"29","DOI":"10.5049\/EBP.2021.19.2.29","volume":"19","author":"HJ Kim","year":"2021","unstructured":"Kim HJ (2021) Metabolic Acidosis in chronic kidney disease: pathogenesis, clinical consequences, and treatment. Electrolyte Blood Press 19(2):29\u201337","journal-title":"Electrolyte Blood Press"},{"key":"10461_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.114197","volume":"158","author":"R Fernandez-Prado","year":"2023","unstructured":"Fernandez-Prado R et al (2023) Sodium zirconium cyclosilicate and metabolic acidosis: potential mechanisms and clinical consequences. Biomed Pharmacother 158:114197","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"10461_CR98","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1002\/ehf2.13976","volume":"9","author":"A Esteban-Fern\u00e1ndez","year":"2022","unstructured":"Esteban-Fern\u00e1ndez A et al (2022) Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life. ESC Heart Fail 9(5):3071\u20133078","journal-title":"ESC Heart Fail"},{"issue":"24","key":"10461_CR99","doi-asserted-by":"publisher","first-page":"9474","DOI":"10.3390\/ijms21249474","volume":"21","author":"Y Patel","year":"2020","unstructured":"Patel Y, Joseph J (2020) Sodium intake and heart failure. Int J Mol Sci 21(24):9474","journal-title":"Int J Mol Sci"},{"issue":"13","key":"10461_CR100","doi-asserted-by":"publisher","first-page":"4744","DOI":"10.3390\/ijms21134744","volume":"21","author":"S Borrelli","year":"2020","unstructured":"Borrelli S et al (2020) Sodium intake and chronic kidney disease. Int J Mol Sci 21(13):4744","journal-title":"Int J Mol Sci"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-024-10461-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-024-10461-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-024-10461-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T08:17:46Z","timestamp":1738829866000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-024-10461-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":100,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["10461"],"URL":"https:\/\/doi.org\/10.1007\/s10741-024-10461-3","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,27]]},"assertion":[{"value":"21 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All the authors have read and approved the final version of the manuscript and gave their consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"C.F received consultancy fees, lectures, or sponsorship of scientific meetings from AstraZeneca, Bayer, Bial, Boehringer Ingelheim, Novartis, Novo Nordisk, Pfizer, Roche Diagnosis, Servier, CSL Vifor, companies that research and commercialize drugs for the treatment of heart failure patients. G.C. received speaking fees from Servier, Novartis, CSL Vifor, and Boehringer. C.G. is employed by Fresenius Medical Care as Head of the Nutrition Department. G.S. received speaking fees from CSL Vifor, AstraZeneca, Alnylam and Baxter. I.M. received speaking fees from AstraZeneca, Bayer, Bial, CSL Vifor, Daiichi-Sankyo, Novartis, Pfizer, Roche Diagnostics, and Servier. I.M. served on advisory boards for AstraZeneca, Bayer, Bial, CSL Vifor, Novartis, Novo Nordisk, and Servier. A.F. received Advisory Board and consultancy fees, lectures, or sponsorship of scientific meetings from AstraZeneca, Astellas, CSL Vifor, Fresenius Medical Care, MSD-Merck Sharp & Dohme companies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}